Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation

Reduction of severe acute graft-versus-host disease using a combination of pre transplant... Bone Marrow Transplantation (2018) 53:361–365 https://doi.org/10.1038/s41409-017-0053-9 CORRESPONDENCE Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation 1 2 1 1 1 ● ● ● ● ● Uday Deotare Eshetu G. Atenafu David Loach Fotios V. Michelis Dennis (Dong-Hwan) Kim 1 1 1 1 ● ● ● Santhosh Thyagu Jeffrey H. Lipton Hans A. Messner Auro Viswabandya Received: 2 May 2017 / Revised: 6 October 2017 / Accepted: 23 October 2017 / Published online: 21 December 2017 © Macmillan Publishers Limited, part of Springer Nature 2018 Use of Post-transplant Cyclophosphamide (PTCy) has associated with severe forms of GVHD. Here we present recently been introduced specifically in the haplo-identical the preliminary outcome in our unrelated patients using transplant setting with promising results [1]. This inter- this regimen. vention has also shown a significant reduction of acute This is a retrospective study of the patient cohort treated graft versus host disease (aGVHD) and a trend towards from 1 October 2015 until 31 March 2016 in a single center. improving chronic graft versus host disease (cGVHD) [2]. This study was approved by the institutional Research The efficacy of PTCy has http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bone Marrow Transplantation Springer Journals

Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation

Loading next page...
1
 
/lp/springer_journal/reduction-of-severe-acute-graft-versus-host-disease-using-a-VF6JGu4zjC

References (12)

Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s) 2017, under exclusive licence to Macmillan Publishers Limited, part of Springer Nature
Subject
Medicine & Public Health; Medicine/Public Health, general; Internal Medicine; Cell Biology; Public Health; Hematology; Stem Cells
ISSN
0268-3369
eISSN
1476-5365
DOI
10.1038/s41409-017-0053-9
Publisher site
See Article on Publisher Site

Abstract

Bone Marrow Transplantation (2018) 53:361–365 https://doi.org/10.1038/s41409-017-0053-9 CORRESPONDENCE Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation 1 2 1 1 1 ● ● ● ● ● Uday Deotare Eshetu G. Atenafu David Loach Fotios V. Michelis Dennis (Dong-Hwan) Kim 1 1 1 1 ● ● ● Santhosh Thyagu Jeffrey H. Lipton Hans A. Messner Auro Viswabandya Received: 2 May 2017 / Revised: 6 October 2017 / Accepted: 23 October 2017 / Published online: 21 December 2017 © Macmillan Publishers Limited, part of Springer Nature 2018 Use of Post-transplant Cyclophosphamide (PTCy) has associated with severe forms of GVHD. Here we present recently been introduced specifically in the haplo-identical the preliminary outcome in our unrelated patients using transplant setting with promising results [1]. This inter- this regimen. vention has also shown a significant reduction of acute This is a retrospective study of the patient cohort treated graft versus host disease (aGVHD) and a trend towards from 1 October 2015 until 31 March 2016 in a single center. improving chronic graft versus host disease (cGVHD) [2]. This study was approved by the institutional Research The efficacy of PTCy has

Journal

Bone Marrow TransplantationSpringer Journals

Published: Dec 21, 2017

There are no references for this article.